

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:
Jaume Pons, et al.

Serial No.: 10/584,443

Confirmation No.: 4751

Filed: August 17, 2007

For: AGONIST ANTI-TRKC ANTIBODIES
AND METHODS USING SAME

Group Art Unit: 1643

Examiner: Anne Gussow

Attorney Docket No.: PC19492A

Mail Stop: Amendment
Commissioner For Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TRANSMITTAL OF INFORMATION DISCLOSURE STATEMENT

UNDER 37 C.F.R. § 1.97

37 CFR § 1.97(b)

- ☐ The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); within three months of the date of entry of the national stage as set forth in § 1.491 in an international application; before the mailing of a first Office Action on the merits; or before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.

37 CFR § 1.97(c)

- ☒ The Information Disclosure Statement submitted herewith is being filed after three months of the filing date of a national application other than a continued prosecution application under § 1.53(d); after three months of the date of entry of the national stage as set forth in § 1.491 in an international application; after the mailing of a first Office Action on the merits; or after the mailing of a first Office Action after the filing of a request for continued examination under § 1.114, but before the mailing date of (1) a Final Action under § 1.113; (2) a Notice of Allowance under § 1.311; or (3) an action that otherwise closes prosecution in the application. The Commissioner is hereby authorized to charge the fee as set forth in § 1.17(p) to Deposit Account Number 16-1445.

- ☐ Applicant requests that the Examiner consider the following copending applications:

Application Serial No.	Filing Date

- ☐ Copies of these copending applications are enclosed.
- ☒ Applicant hereby requests consideration of the Information Disclosure Statement, PTO/SB/08, submitted herewith. Copies of the cited references, except as noted below, are enclosed.
- ☐ This application is a continuation, divisional or continuation-in-part of Serial No. [REDACTED]. Copies of the cited references, if not enclosed, are available in the file of the parent application or parents thereof.
- ☐ Copies of U.S. Patents and U.S. Patent Application Publications are not enclosed. (waiver of 37 CFR 1.98(a)(2)(iii) pursuant to 37 CFR 1.183).
- ☐ Applicant hereby requests consideration of the enclosed International Search Report, which was received in a related international patent application.

The Commissioner is hereby authorized to charge any fee deficiency, including any fee required under 37 C.F.R. § 1.17(p), or credit any overpayment, to Deposit Account Number 16-1445.

Respectfully submitted,

Date: February 8, 2011

/Deborah.A.Martin/
Deborah A. Martin
Attorney For Applicant
Registration No. 44,222

Pfizer Inc.
Patent Department
10555 Science Center Drive
San Diego, California 92121
Phone: 650.615.7375
Fax: 650.615.7501
Email: deborah.a.martin@pfizer.com